TargetBeta
KCNJ11
potassium inwardly rectifying channel subfamily J member 11 · also Kir6.2, BIR · Potassium inwardly rectifying channel subfamily J
3 programs in company-led studies act on KCNJ11, from 3 companies: 1 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| repagliniderule | Novo Nordisk | inhibitor | phase 4 | 323 running | ABCC8 | ChEMBL |
| mitigliniderule | Kissei Pharmaceutical | inhibitor | phase 4 | 90 running | ABCC8 | ChEMBL |
| Minoxidilrule | Industrial Farmacéutica Cantabria | – | phase 3 | 133 running | ABCC9 | ChEMBL |
Conditions their studies are in
- Diabetes Mellitus, Type 2, 2 programs
- Alopecia, 1 program
- Diabetes Mellitus, 1 program
- Gastrointestinal Stromal Tumors, 1 program
- Gout, 1 program
- Hypotrichosis, 1 program
- Obesity, 1 program
- Overweight, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2027repaglinide · Novo Nordisk · phase 4 · NCT07372625
- Oct 30, 2028Minoxidil · Industrial Farmacéutica Cantabria · phase 3 · NCT07529977
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.